HGR4113
HGR4113 is an orally active anti-inflammatory/antioxidant agent with improved glucose metabolism. HGR4113 inhibits STAT3 phosphorylation, suppresses Th17 differentiation and IL-17 production, reduces oxidative phosphorylation activity, and promotes the differentiation of regulatory T cells among splenic CD4+ T cells. HGR4113 inhibits LPS (HY-D1056)-induced JNK phosphorylation, production of NO, PGE2 and pro-inflammatory cytokines, expression of iNOS and COX-2, as well as nuclear translocation of NF-κB in macrophages, while induces HO-1 expression by activating nuclear translocation of Nrf2. HGR4113 can be used in the research of inflammatory diseases such as type 2 diabetes and Sjögren's syndrome.
For research use only. We do not sell to patients.
- CAS No.: 2170918-46-2
- Formula: C23H28O4
- Molecular Weight:368.47
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
STAT3 |
iNOS |
COX-2 |
IL-17 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | IC50 |
11.32 μM
|
Inhibition of LPS-induced nitric oxide production in RAW264.7 macrophages assessed via Griess reaction after 3 h pre-treatment with reagent followed by 24 h LPS stimulation.
Inhibition of LPS-induced nitric oxide production in RAW264.7 macrophages assessed via Griess reaction after 3 h pre-treatment with reagent followed by 24 h LPS stimulation.
|
36903379 |
| RAW264.7 | IC50 |
1.64 μM
|
Inhibition of LPS-induced prostaglandin E2 production in RAW264.7 macrophages assessed via ELISA after 3 h pre-treatment with reagent followed by 24 h LPS stimulation.
Inhibition of LPS-induced prostaglandin E2 production in RAW264.7 macrophages assessed via ELISA after 3 h pre-treatment with reagent followed by 24 h LPS stimulation.
|
36903379 |
In Vitro
HGR4113 (1-10 μM; 74 h) reduces the viability of stimulated splenocytes in a dose-dependent manner, and inhibits the production of pro-inflammatory cytokines IFNγ, IL-17, TNF-α and IL-6 in splenocytes from C57BL/6 and NOD/ShiLtJ mice stimulated with anti-CD3/anti-CD28 antibodies or LPS[1].
HGR4113 (1-10 μM; 74 h) dose-dependently inhibits Th17 differentiation and pro-inflammatory cytokine production, promotes Treg differentiation, suppresses STAT3 phosphorylation, and reduces OXPHOS activity in purified splenic CD4+ T cells from C57BL/6 mice[1].
HGR4113 (1-10 μM; 98 h) dose-dependently shifts the polarization of B cells from proinflammatory IL-17-producing cells to regulatory IL-10-producing cells, reduces immunoglobulin production, and modulates the mRNA expression of B cell activation- and fibrosis-related genes in purified splenic CD19+ B cells from C57BL/6 mice[1].
HGR4113 (27 h) inhibits LPS-induced NO production in RAW264.7 macrophages in a dose-dependent manner, with an IC50 of 11.32 μM[2].
HGR4113 (5-20 μM; 27 h) reduces LPS-induced iNOS and COX-2 protein expression in RAW264.7 macrophages in a dose-dependent manner[2].
HGR4113 (5-20 μM; 4 h) inhibits LPS-induced NF-κB activation in RAW264.7 macrophages in a dose-dependent manner by reducing the phosphorylation level of IκB-α, NF-κB nuclear translocation, and NF-κB DNA-binding activity[2].
HGR4113 (5-20 μM; 3.5 h) dose-dependently inhibits LPS-induced phosphorylation of JNK in RAW264.7 macrophages without affecting the phosphorylation of ERK or p38[2].
HGR4113 (5-20 μM; 12 h) dose-dependently induces the expression of HO-1 protein in RAW264.7 macrophages[2].
HGR4113 (20 μM; 0.5-1.5 h) induces nuclear translocation of Nrf2 in RAW264.7 macrophages, increases nuclear Nrf2 levels and decreases cytoplasmic Nrf2 levels over time[2].
HGR4113 (20 μM; 15 h) induces the expression of HO-1 protein in RAW264.7 macrophages via the ERK MAPK pathway, while the p38 and JNK MAPK pathways exert negative regulatory effects on this induction process[2].
HGR4113 (5-20 μM; 27 h) dose-dependently inhibits LPS-induced PGE2 production in RAW264.7 macrophages, with an IC50 value of 1.64 μM[2].
HGR4113 (5-20 μM; 9 h) dose-dependently inhibits LPS-induced expression of IL-1β, IL-6 and TNF-α mRNA in RAW264.7 macrophages[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 macrophages
-
Concentration:5, 10 20 μM
-
Incubation Time:3 h pre-treatment, followed by 24 h LPS stimulation
-
Result:Dose-dependently reduced LPS-induced PGE2 production.
Inhibited PGE2 production with an IC50 of 1.64 μM.
Showed inhibitory effects comparable to the positive control butein at 20 μM.
-
Cell Line:RAW264.7 macrophages
-
Concentration:5, 10 and 20 μM
-
Incubation Time:3 h pre-treatment, followed by 24 h LPS stimulation
-
Result:Dose-dependently reduced LPS-induced iNOS and COX-2 protein expression.
Reduced iNOS protein levels to 0.64 relative to actin at 20 μM.
Reduced COX-2 protein levels to 0.65 relative to actin at 20 μM.
-
Cell Line:RAW264.7 macrophages
-
Concentration:5, 10 and 20 μM
-
Incubation Time:3 h pre-treatment, followed by 6 h LPS stimulation
-
Result:Dose-dependently reduced LPS-induced IL-1β, IL-6, and TNF-α mRNA expression.
Showed inhibitory effects comparable to the positive control butein at 20 μM.
-
Cell Line:RAW264.7 macrophages
-
Concentration:5, 10 and 20 μM
-
Incubation Time:3 h pre-treatment, followed by 30 min LPS stimulation
-
Result:Dose-dependently reduced LPS-induced JNK phosphorylation.
Showed no effect on ERK or p38 phosphorylation.
Reduced p-JNK levels to 0.54 relative to actin at 20 μM.
Left total unphosphorylated MAPK levels unaffected.
-
Cell Line:RAW264.7 macrophages
-
Concentration:5-20 μM
-
Incubation Time:12 h
-
Result:Dose-dependently increased HO-1 protein expression.
Increased HO-1 levels to 1.84 relative to actin at 20 μM.
-
Cell Line:RAW264.7 macrophages
-
Concentration:20 μM
-
Incubation Time:0.5, 1, 1.5 h
-
Result:Increased nuclear Nrf2 expression over the 1.5 h treatment period.
Decreased cytosolic Nrf2 expression over the 1.5 h treatment period.
Increased nuclear Nrf2 levels to 1.92 relative to PCNA at 1.5 h.
Decreased cytosolic Nrf2 levels to 0.60 relative to actin at 1.5 h.
-
Cell Line:RAW264.7 macrophages
-
Concentration:20 μM
-
Incubation Time:12 h after 3 h pre-incubation with MAPK inhibitors
-
Result:Reduced HO-1 expression to 0.70 relative to actin when pre-treated with ERK inhibitor PD98059 (HY-12028).
Increased HO-1 expression to 1.13 relative to actin when pre-treated with p38 inhibitor SB203580 (HY-10256).
Increased HO-1 expression to 1.55 relative to actin when pre-treated with JNK inhibitor SP600125 (HY-12041).
Parmacokinetics
| Species | Dose | Route | Cmax |
|---|---|---|---|
| Mice[1] | 160 mg/kg | p.o. | 4.90 μg/mL |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/ShiLtJ (8-week-old female)[1]
-
Dosage:100 mg/kg
-
Administration:p.o.; once daily; 12 weeks
-
Result:Maintained higher salivary flow rates than vehicle-treated mice through week 20.
Reduced serum total IgG levels.
Decreased salivary gland infiltration of CD4+ cells, CD19+ cells, IL-6+ cells, and IL-17+ cells.
Reduced splenic frequencies of Th17 cells, CD4+ICOS+IFNγ+Bcl6+ follicular helper T cells, CD4+ICOS+IL-17+Bcl6+ follicular helper T cells, germinal-centre B cells, and plasma cells.
Reduced salivary gland fibrosis area, collagen I-positive area, fibronectin-positive area, and TGF-β-positive area; increased aquaporin-5-positive area in salivary glands.
Enhanced formation of 3D salivary epithelial structures, with increased fluorescence intensity of E-cadherin, aquaporin-5, α-SMA, and cytokeratin-14 in these structures.
Chemical Information
-
CAS No. 2170918-46-2
-
Molecular Weight 368.47
-
Formula C23H28O4
-
SMILES
CCCOC1=CC=C(C(O)=C1)[C@@H]2COC3=C4CCC(C)(OC4=CC=C3C2)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)